Communiqués Dimerix Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 08:10:14 11/08/2026			Varia. 5j.	Varia. 1 janv.
0,2850 ^AUD	+3,64%		+9,62%	-48,18%

23/07	Dimerix obtient un brevet américain pour son candidat-médicament contre l'insuffisance rénale, l'action grimpe de 4 %	MT
17/07	Dimerix Limited et Mission Therapeutics Limited élargissent leur pipeline avec l'acquisition d'un actif prêt pour la phase 2 dans l'insuffisance rénale aiguë	CI

17/07	Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline	AQ
17/06	Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia	AQ
05/10/23	ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	AQ
27/07/22	Dimerix : Quarterly Appendix 4C and Activities Report	PU
06/06/22	Dimerix : to Present at BIO International Convention	PU
27/04/22	Dimerix : Quarterly Appendix 4C and Activities Report	PU
01/03/22	Dimerix : Investor Call and Presentation	PU
24/02/22	Dimerix : Half-Year Financial Report & Appendix 4D - 31 December 2021	PU
06/12/21	Dimerix : Notification regarding unquoted securities - DXB	PU
29/07/20	DIMERIX : DMX-200 Posts Strong Results in Kidney Disease Trial	BU
24/11/19	Dimerix : Holds Pre-IND Meeting on DMX-200 With FDA	PU